Wells Fargo analyst Colin Langan upgraded Cerence Inc. from Equal-Weight to Overweight and an $85 price target, down from $91, implying a 15 percent upside.
Langan noted Cerence is down about 50 percent from its high and 34 percent since reporting FY21 results and guiding below consensus for FY22.
